NLRP3 and breast cancer: According to these findings, the therapeutic approach with of NLRP3 and caspase-1 (MCC950 or Ac-YVAD-cmk) inhibitors is able to attenuate breast cancer cells growth [147] demonstrating that caspase 1 blockade can inhibit inflammatory responses regulated by both cytokines- and pyroptosis-dependent inflammasome.